Accueil>>Signaling Pathways>> Others>>CCG258208 hydrochloride

CCG258208 hydrochloride (Synonyms: GRK2-IN-1 hydrochloride)

Catalog No.GC62891

Le chlorhydrate de CCG258208 (GRK2-IN-1) est un inhibiteur puissant et sélectif de GRK2 (récepteur couplé aux protéines G kinase 2) (IC50 = 30 nM) tout en maintenant une sélectivité de 230 fois par rapport À GRK5 (IC50 = 7,09 μM) et plus de 2500- plier la sélectivité sur GRK1 (IC50 = 87,3 μM), PKA et ROCK1.

Products are for research use only. Not for human use. We do not sell to patients.

CCG258208 hydrochloride Chemical Structure

Taille Prix Stock Qté
10mM (in 1mL DMSO)
338,80 $US
En stock
1 mg
108,00 $US
En stock
2 mg
180,00 $US
En stock
5 mg
315,00 $US
En stock
10 mg
495,00 $US
En stock
25 mg
891,00 $US
En stock
50 mg
1 485,00 $US
En stock
100 mg
2 025,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GRKs-IN-1 hydrochloride, Compound 14as, has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50=130 nM) and GRK5 (IC50=7.1 μM).GRKs-IN-1 hydrochloride is a derivative 14as of paroxetine, shows a 100-fold improvement in cardiomyocyte contractility assays over paroxetine[1].

[1]. Waldschmidt HV, et al. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2Inhibitors Based on Paroxetine. J Med Chem. 2017 Apr 13;60(7):3052-3069.

Avis

Review for CCG258208 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CCG258208 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.